Catalog No.
PAC90701
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Obinutuzumab
Applications
ELISA
Recommended Dilution
| Application |
Dilution |
| ELISA |
1:4000-1:8000 |
Target
Rabbit polyclonal to Gazyva.
Specificity
The product is specific for Obinutuzumab. This antibody serves as an excellent positive control for Obinutuzumab immunogenicity (ADA) assays.
Concentration
0.21 mg/ml
Purification
Purified by antigen affinity column.
Accession
CAS: 949142-50-1
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.
Note
Antibodysystem can customize this product per customer's request including product size, buffer components, etc. For research use only.
In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumab., PMID:39663256
SOHO State of the Art Updates and Next Questions | Venetoclax + Obinutuzumab Therapy in Chronic Lymphocytic Leukemia., PMID:39732538
Acalabrutinib and Obinutuzumab for Chronic Lymphocytic Leukemia Complicated With Peripheral Neuropathy., PMID:39734995
Obinutuzumab-induced acute thrombocytopenia: a case report and literature review., PMID:39741978
The treatment combination of obinutuzumab, bendamustine and dexamethasone achieved a deeper response than the previous line of treatment in five patients with Waldenström's macroglobulinemia., PMID:39772823
The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma., PMID:39776016
Decoding the molecular interplay of CD20 and therapeutic antibodies with fast volumetric nanoscopy., PMID:39787234
Successful Switch to Obinutuzumab in a Rituximab-Intolerant Child with Difficult-to-Treat Idiopathic Nephrotic Syndrome., PMID:39797329
Efficacy, safety and cost-effectiveness of obinutuzumab in patients with follicular lymphoma: a rapid review., PMID:39830356
Obinutuzumab in Difficult to Treat Phospholipase A2 Receptor Positive Membranous Nephropathy: Our Experience at a Tertiary Care Center in North India., PMID:39872260
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial., PMID:39883943
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis., PMID:39927615
Two Are Better than One: The Bi-Specific Antibody Mosunetuzumab Reveals an Improved Immune Response of Vγ9Vδ2 T Cells Targeting CD20 in Malignant B Cells in Comparison to the Mono-Specific Antibody Obinutuzumab., PMID:39941030
Efficacy and Safety of First-line Targeted Therapies in Physically Fit Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis., PMID:39952822
Low-dose obinutuzumab for steroid-dependent nephrotic syndrome complicated by recurrent rituximab-induced serum sickness and anti-rituximab antibodies., PMID:39966139
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia., PMID:39976417
Obinutuzumab in Rituximab-resistant and recurrent membranous nephropathy: a case-series., PMID:39979558
Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study)., PMID:39997358
Antibody Therapy for Patients with Lymphoid Malignancies: Past and Present., PMID:40004173
Chemotherapy-free treatment with acalabrutinib can benefit patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were never treated before: a plain language summary of the ELEVATE-TN study., PMID:40007474
t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumab., PMID:40014084
Obinutuzumab in membranous nephropathy: a potential game-changer in treatment., PMID:40017729
Observation of the efficacy and safety of obinutuzumab in the treatment of refractory idiopathic membranous nephropathy., PMID:40025315
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma., PMID:40030008
[Immune thrombotic thrombocytopenic purpura treated with Obinutuzumab: a case report and literature review]., PMID:40032339
[The combined regimen based on obinutuzumab plus glucocorticoid for 4 cases of relapsed iTTP]., PMID:40059685
Bilateral drusenoid deposits with subretinal fluid and cystoid macular edema in a serum anti-phospholipase A2 receptor antibody positive patient: A case report., PMID:40061915
Anti-CD20 maintenance strategies to face the challenge of COVID-19 pandemic in follicular lymphoma: results from the R-FolSTOP multicentre Italian study., PMID:40074837
The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease., PMID:40104551
Preclinical B cell depletion and safety profile of a brain-shuttled crystallizable fragment-silenced CD20 antibody., PMID:40118783
Treatment of nephrotic syndrome with anti-CD20 therapies in pregnancy: a case series and review of the literature., PMID:40148078
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study., PMID:40181090
A New Pulmonary Nodule in a Patient With a History of Lymphoma., PMID:40210319
B cell depletion in lupus nephritis: From disappointments to hopes, despite some concerns., PMID:40220749
AMPLIFY: A second-generation BTK inhibitor for fixed-duration therapy in chronic lymphocytic leukemia., PMID:40220751
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies., PMID:40225374
Clinical characteristics, treatment patterns and outcomes of patients with follicular lymphoma in Colombia: a real-world evidence cohort study., PMID:40227475
How we manage immune-mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance., PMID:40270461
Osteonecrosis of the Jaw Associated with Obinutuzumab in a Patient with Preceding Follicular Non-Hodgkin's Lymphoma., PMID:40278317
Obinutuzumab in Rituximab-Intolerant Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Patients., PMID:40303206
Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A2 receptor antibody: case reports., PMID:40303416
[Seronegativity and anti-CD20: When a treatment compromises the diagnosis]., PMID:40312237
Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy., PMID:40336511
Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia - real-world data from a hemato-oncology center., PMID:40353625
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403., PMID:40355425
Early caplacizumab and obinutuzumab enable successful treatment of relapsing thrombotic thrombocytopenic purpura without therapeutic plasma exchange: a case report., PMID:40356910
Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy., PMID:40388905
Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis., PMID:40421460
Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?, PMID:40427101
Advances and challenges in leukemia treatment: A focus on monoclonal antibodies and emerging therapies., PMID:40486885
For research use only. Not for human or drug use.
